Last reviewed · How we verify
Teriflunomide HMR1726
Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes.
Teriflunomide inhibits dihydroorotate dehydrogenase, an enzyme required for pyrimidine synthesis, thereby reducing proliferation of activated lymphocytes. Used for Relapsing-remitting multiple sclerosis (RRMS), Secondary progressive multiple sclerosis (SPMS).
At a glance
| Generic name | Teriflunomide HMR1726 |
|---|---|
| Also known as | Aubagio |
| Sponsor | Sanofi |
| Drug class | Dihydroorotate dehydrogenase inhibitor; immunosuppressant |
| Target | Dihydroorotate dehydrogenase (DHODH) |
| Modality | Small molecule |
| Therapeutic area | Immunology; Neurology |
| Phase | FDA-approved |
Mechanism of action
By blocking dihydroorotate dehydrogenase, teriflunomide depletes pyrimidine nucleotides needed for DNA and RNA synthesis, selectively suppressing the proliferation of T and B lymphocytes that depend on de novo pyrimidine synthesis. This immunosuppressive effect reduces the inflammatory cascade in autoimmune diseases. The drug is the active metabolite of leflunomide and has a long half-life allowing once-daily dosing.
Approved indications
- Relapsing-remitting multiple sclerosis (RRMS)
- Secondary progressive multiple sclerosis (SPMS)
Common side effects
- Headache
- Diarrhea
- Nausea
- Elevated liver enzymes
- Alopecia
- Hypertension
Key clinical trials
- Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (PHASE1, PHASE2)
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (PHASE3)
- A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. (PHASE3)
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
- Teriflunomide Plus High-dose Dexamethasone as First-line Treatment in Newly Diagnosed Primary Immune Thrombocytopenia (PHASE2)
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2) (PHASE3)
- Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Teriflunomide HMR1726 CI brief — competitive landscape report
- Teriflunomide HMR1726 updates RSS · CI watch RSS
- Sanofi portfolio CI